文献速递心律失常

改善心房颤动治疗:是否存在相关基因?

Improving Atrial Fibrillation Therapy: Is There a Gene for That?
PubMed 文献 · J Am Coll Cardiol · 2017-01-01

心房颤动(AF)常见且治疗困难,现有疗法疗效有限且复发率高。本综述汇总了AF基因治疗在临床前模型中的已发表数据,讨论其靶向递送、组织特异性和针对心律失常机制的潜力,以及迈向临床转化仍面临的挑战与局限。

要点

  • AF现有治疗疗效有限且复发率高,基因治疗在临床前模型中显示出靶向递送和组织特异性潜力。
  • 基因治疗旨在针对心律失常 underlying 机制进行定制化治疗。
  • 基因治疗在成为临床相关AF治疗前仍面临诸多挑战。

核心结论

  • 基因治疗在AF临床前模型中显示出作为靶向治疗方式的潜力,但转化为临床相关治疗前仍有许多挑战。

研究设计与样本

  • 综述:汇总已发表的AF基因治疗临床前研究数据,讨论挑战、机遇与局限。

主要发现

  • 现有AF治疗疗效有限且复发率高。
  • 基因治疗具有靶向递送、组织特异性和针对心律失常机制的定制治疗潜力。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Atrial fibrillation (AF) is an all-too-common and often challenging reality of clinical care. AF leads to significant morbidity and mortality; however, currently available treatments for AF have modest efficacy and high recurrence rates. In recent years, genetic therapy approaches have been explored in preclinical models of AF, and offer potential as a treatment modality with targeted delivery, tissue specificity, and therapy tailored to address mechanisms underlying the arrhythmia. However, many challenges remain before gene therapy can advance to a clinically relevant AF treatment. In this review, we summarize the available published data on gene therapy and discuss the challenges, opportunities, and limitations of this approach.

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Hucker WJ, Hanley A, Ellinor PT, et al. Improving Atrial Fibrillation Therapy: Is There a Gene for That? J Am Coll Cardiol. 2017. PMID: 28427583. doi:10.1016/j.jacc.2017.02.043

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。